Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors June 26, 2026
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares June 5, 2026
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy June 1, 2026
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy May 29, 2026
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody May 26, 2026
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy May 26, 2026
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update May 7, 2026